Salemi A, Sedrakyan A, Mao J, Elmously A, Wijeysundera H, Tam DY, Di Franco A, Redwood S, Girardi LN, Fremes SE et al..
2019.
Individual Operator Experience and Outcomes in Transcatheter Aortic Valve Replacement.. JACC Cardiovasc Interv. 12(1):90-97.
Grossman LV, Creber RMMasterso, Benda NC, Wright D, Vawdrey DK, Ancker JS.
2019.
Interventions to increase patient portal use in vulnerable populations: a systematic review.. J Am Med Inform Assoc. 26(8-9):855-870.
Kasabwala K, Patel N, Cricco-Lizza E, Shimpi AA, Weng S, Buchmann RM, Motanagh S, Wu Y, Banerjee S, Khani F et al..
2019.
The Learning Curve for Magnetic Resonance Imaging/Ultrasound Fusion-guided Prostate Biopsy.. Eur Urol Oncol. 2(2):135-140.
Veinot TC, Ancker JS, Cole-Lewis H, Mynatt ED, Parker AG, Siek KA, Mamykina L.
2019.
Leveling Up: On the Potential of Upstream Health Informatics Interventions to Enhance Health Equity.. Med Care. 57 Suppl 6 Suppl 2:S108-S114.
Sharaf RN, Venkatesan T, Shah R, Levinthal DJ, Tarbell SE, Jaradeh SS, Hasler WL, Issenman RM, Adams KA, Sarosiek I et al..
2019.
Management of cyclic vomiting syndrome in adults: Evidence review.. Neurogastroenterol Motil. 31 Suppl 2:e13605.
Hirst A, Philippou Y, Blazeby J, Campbell B, Campbell M, Feinberg J, Rovers M, Blencowe N, Pennell C, Quinn T et al..
2019.
No Surgical Innovation Without Evaluation: Evolution and Further Development of the IDEAL Framework and Recommendations.. Ann Surg. 269(2):211-220.
Greenlee H, Shi Z, Hibshoosh H, Giri DD, Ahmed A, Williams S, Falcone DJ, Winston LA, Zhou XK, Hudis CA et al..
2019.
Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients.. Cancer Prev Res (Phila). 12(1):21-30.
Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling LA, Dittus C, Chen Z, Huang X et al..
2019.
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.. Blood. 133(11):1201-1204.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..
2019.
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.